

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Androgen receptor	<p>Studies in patient samples and in mice identified an androgen receptor splice variant that could help predict risk for castration-resistant prostate cancer. In a mouse xenograft model of human prostate cancer, tumors that expressed an androgen receptor splice variant lacking exons 5–7 were castration resistant, whereas tumors expressing the wild-type receptor were castration sensitive. In patient prostate biopsy samples, expression of the splice variant was higher than that in prostate biopsy samples from healthy controls. Next steps could include confirming the splice variant as a marker for castration-resistant prostate cancer in larger patient cohorts.</p> <p>SciBX 3(30); doi:10.1038/scibx.2010.920 Published online Aug. 5, 2010</p>	Patent and licensing status unavailable	<p>Sun, S. <i>et al.</i> <i>J. Clin. Invest.</i>; published online July 19, 2010; doi:10.1172/JCI41824 Contact: Stephen R. Plymate, University of Washington School of Medicine, Seattle, Wash. e-mail: splymate@u.washington.edu</p>